Genitourinary Cancers

Dr. Brian I. Rini from the Taussig Cancer Institute Explains the Axitinib Integration Process

Dr. Brian Rini from Taussig Cancer Institute explains the Axitinib and Sorafenib AXIS Trial VEGF Potency Focus

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Axitinib and Sorafenib Trial Hazard Ratio

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

Dr. David Cella from Northwestern University Feinberg School of Medicine on the Side Effect Focus of the Axitinib and Sorafenib Trial

Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial

The FDA announced that the prolonged use of pioglitazone (Actos) for more than 1 year has been linked to an increased risk of bladder cancer

Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib

March was National Kidney Month, so here is an opportunity to test your knowledge about kidney cancer.

Kidney cancer resource from across the web including blogs, associations, journals, clinical trials and online CME offerings

The use of microRNAs and proteomics-based approaches for early detection are among the foremost research priorities of the National Cancer Institute

Help kidney cancer patients by being aware of available resources and support services

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, shares information that she feels the public should know about kidney cancer.

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Explains Advancements in Kidney Cancer Over the Past Several Years

Ana M. Molina, MD, Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Gives Advice for Newly Diagnosed Kidney Cancer Patients

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Talks About Pazopanib, Sunitinib and Other Recent Clinical Trials

Erythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase

The past 2 to 3 decades saw a palpable therapeutic nihilism associated with the management of patients with advanced renal cell carcinoma (RCC), interrupted briefly by the initial excitement regarding high-dose interleukin-2.

Fast biotech facts and figures. In this issue: 1) Cancer Risk Factors and Mortality 2) Bladder Cancer 3) Testicular Cancer 4) Breast Cancer

The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 21 leading cancer centers worldwide, develops and publishes clinical practice guidelines to promote the importance of continuous quality improvement. The primary goal of all its initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals.

When the market is volatile, people think about their financial future. With current market events as turbulent as they are, you may be concerned about their potential impact on your 401(k) account. During times like this, it is more important than ever to follow certain basic, time-tested principles of investing.

The next leap forward in cancer treatment will see physicians tailoring treatments based on patients' individualized tumor profiles.